To investigate this, we first validated the endogenous expression levels of IRS1 and IRS2 in all three types of cancer cell lines by using C-CBL targeting si-RNA (si-C-CBL) under prolonged insulin treatment. This evidence concerns the gene IRS2 and cancer.